Health Catalyst Q1 2026 Results: Revenue Decline, Client Migration Issues, and Strategic Shifts - News and Statistics
Health Catalyst reported its Q1 2026 results, showing ongoing restructuring and challenges from client migration, leading to a revenue decline despite exceeding analyst expectations. The company acknowledged customer attrition due to fixed migration schedules but also reported strong new business bookings and progress in cost-reduction. Management addressed analyst concerns regarding services revenue, platform migration, and the new Ignite Intelligence product, indicating a shift towards adapting to client preferences and emphasizing the value of their intelligence layers.
EDGAR Filing Documents for 0001636422-25-000010
This document is an EDGAR filing (Form 8-K) by Health Catalyst, Inc. (CIK: 0001636422) for January 13, 2025. It details the entry into a material definitive agreement, unregistered sales of equity securities, and highlights the company's participation in the J.P. Morgan Healthcare Conference with numerous associated graphic exhibits.
3 Stocks With Recent Gains But Weak Fundamentals, According to May 2026 Analysis
An analysis from May 2026 identifies Health Catalyst (HCAT), Enphase Energy (ENPH), and World Kinect (WKC) as three stocks that have recently shown significant price gains but are underpinned by weak fundamental financial metrics. Health Catalyst struggles with plateaued billings and high marketing costs, Enphase Energy faces declining sales and free cash flow, and World Kinect operates with low gross margins and limited free cash flow. Despite their recent stock performance, the report suggests these companies may not be sustainable long-term investments due to underlying operational and financial challenges.
Health Catalyst: Buy Rating Reaffirmed as Strategic Transformation Supports Long-Term Growth Despite Near-Term Estimate Cuts
William Blair analyst Ryan Daniels has reaffirmed a Buy rating for Health Catalyst (HCAT) despite near-term estimate reductions, citing the company's strategic transformation and attractive long-term growth prospects. Daniels adjusted revenue and EBITDA forecasts to align with management's guidance and the strategic review, expressing confidence in the company's ability to execute its plan. Canaccord Genuity also maintained a Buy rating with a $2.00 price target.
Health Catalyst (HCAT) seeks declassification vote; board, auditor and pay proposals
Health Catalyst (HCAT) is soliciting proxies for its 2026 Annual Meeting on July 16, 2026, where stockholders will vote on electing two Class I directors, ratifying Ernst & Young LLP as auditor, approving an advisory 'say-on-pay' for executive compensation, and a charter restatement to phase out the classified board structure. The board recommends voting FOR all proposals, which include transitioning to annual director elections starting in 2029. The company also detailed its fiscal 2025 executive compensation and performance-based incentives, highlighting a significant portion of executive pay is tied to company performance and stock value.
Health Catalyst stock (US42226A1079): Shares jump after recent trading update
Health Catalyst shares experienced a significant jump after a recent trading update, despite the company reporting higher revenue but a wider net loss in the first half of 2025. The healthcare data and analytics software provider saw its stock increase by approximately 7.98% to $1.28. While recurring technology revenue showed growth, the wider loss indicates ongoing challenges with cost control and profitability.
5 Insightful Analyst Questions From Health Catalyst’s Q1 Earnings Call
Health Catalyst's Q1 earnings revealed a revenue beat but lower full-year guidance, impacted by client churn from a rigid migration strategy. Management addressed analyst questions concerning services mix, client migration hesitancy, AI adoption, and churn composition, emphasizing a shift to a more flexible client-centric approach. The company is focusing on Project NEXUS, stabilizing revenue, and monetizing AI solutions in upcoming quarters.
MongoDB, Health Catalyst, and Qualys Shares Are Soaring, What You Need To Know
MongoDB, Health Catalyst, and Qualys experienced significant stock jumps as investor confidence in software companies rebounded. The market softened its view on AI's existential threat, recognizing that these companies are well-positioned to integrate AI rather than be replaced. This shift suggests a potential re-rating for the software sector after a period of underperformance.
5 Insightful Analyst Questions From Health Catalyst’s Q1 Earnings Call
Health Catalyst's Q1 results showed a revenue beat but a year-on-year decline, as the company grapples with past client migration strategies leading to churn. Despite this, management highlighted strong bookings and progress on cost-saving initiatives. Analysts focused on issues such as shrinking service mix, client migration hesitancy, customer feedback on new AI tools, customer counts by platform, and the composition of churn, providing insight into the company's strategic adjustments and future focus areas.
Health Catalyst stock (US42226A1079): Earnings update keeps focus on path to profitability
Health Catalyst (HCAT) reported its quarterly figures and updated its outlook, keeping investor attention on its dual focus of growth and profitability within the healthcare data analytics market. The company specializes in providing data and analytics solutions to US healthcare providers, aiming to improve care quality and reduce costs through recurring software subscriptions and professional services. Investors are keen on the company's ability to expand its customer base, grow recurring revenue, and narrow losses, as it represents exposure to the digitalization of the US healthcare system.
Health Catalyst Inc stock (US42226A1079): earnings update keeps focus on AI-driven healthcare analytics
Health Catalyst Inc recently released its quarterly results, highlighting its focus on AI-driven solutions in a challenging healthcare IT market. The company specializes in data and analytics for healthcare providers and payers, offering subscription software, data platforms, and professional services. Its business model thrives on recurring revenue from multi-year contracts, targeting large health systems and aligning with the industry's shift towards value-based care and advanced analytics.
Number of shareholders of Health Catalyst, Inc. – DUS:2YP
This page provides financial information for Health Catalyst, Inc. (DUS:2YP) on the Dusseldorf Stock Exchange, focusing on the number of shareholders. It includes an overview of the company's financials and various data sources, including ICE Data Services and FactSet. The article emphasizes the availability of financial data and news for the company on the TradingView platform.
Health Catalyst (NASDAQ: HCAT) group reports 8.3% stake in amended 13G/A
An amended 13G/A SEC filing reveals that various entities collectively hold a significant stake in Health Catalyst (NASDAQ: HCAT). Stoney Lonesome HF LP holds 8.3%, Drake Helix Holdings, LLC holds 0.3%, and CDC Financial, Inc., along with Clint D. Coghill, are deemed beneficial owners of approximately 8.6% of the company's outstanding shares. The filing provides detailed ownership percentages and share counts based on 73,586,183 shares outstanding as of March 5, 2026.
Health Catalyst stock (US42226A1079): Q1 beat with EPS of $0.02, revenue $70.76M
Health Catalyst reported a strong Q1 2026, surpassing analyst expectations with an adjusted EPS of $0.02 against a projected $0.01 and revenue reaching $70.76 million, exceeding the $69.24 million consensus. The company, focused on healthcare data analytics, demonstrated resilience in a challenging market. Despite ongoing GAAP unprofitability, it shows progress in adjusted metrics, driven by software subscriptions and analytics services.
Health Catalyst Q1 earnings call highlights
This article provides highlights from Health Catalyst's Q1 earnings call. It is expected to cover key financial results, operational updates, and potentially future guidance or strategic initiatives discussed during the call.
Health Catalyst Q1 2026 Earnings Preview
This article provides a brief preview of Health Catalyst's (HCAT) Q1 2026 earnings. It notes that the company is expected to announce earnings on May 15, 2026. Further details are awaited with the official announcement.
Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Liquidia Technologies (LQDA) and Bicara Therapeutics Inc. (BCAX)
This article summarizes recent analyst ratings for three healthcare companies. Health Catalyst (HCAT) received a Hold rating from BTIG and TipRanks – Anthropic, with an average price target offering a 43.7% upside. Liquidia Technologies (LQDA) was rated Buy by BTIG, with a significant 23.4% upside from its average price target, and Bicara Therapeutics Inc. (BCAX) garnered a Strong Buy consensus, with BTIG and Guggenheim reiterating Buy ratings and a 35.9% upside.
Health Catalyst (HCAT) Trailing EPS Loss Worsens And Reinforces Bearish Profitability Narratives
Health Catalyst (HCAT) reported a widening basic EPS loss of US$1.53 in Q1 2026, alongside declining revenue. Over the last twelve months, the company's net loss deepened to US$265.3 million on US$302.5 million of revenue, supporting bearish concerns about client budget cuts and a challenging path to profitability. Despite a low P/S ratio compared to peers, the stock trades above its DCF fair value, and profitability is not forecast within the next three years.
Health Catalyst Is Maintained at Equal-Weight by Stephens & Co.
This article reports that Stephens & Co. has maintained an Equal-Weight rating on Health Catalyst. No further details are provided in the current content.
Goodwill hit reshapes Health Catalyst (Nasdaq: HCAT) Q1 2026 results
Health Catalyst (HCAT) reported its Q1 2026 results, showing an 11% decline in revenue to $70.8 million but an improved non-GAAP profitability. The company posted a significant GAAP net loss of $111.0 million, primarily due to a $95.5 million goodwill impairment charge in its Technology reporting unit. Despite the loss, Adjusted EBITDA increased by 46% to $9.1 million, and management provided guidance for full-year 2026 revenue of $260–$265 million and Adjusted EBITDA of $30–$33 million, while acknowledging potential client churn from their DOS to Ignite migration.
Health Catalyst (HCAT) Stock Trades Up, Here Is Why
Health Catalyst (HCAT) shares rose 9.4% after the company reported first-quarter 2026 results that exceeded analyst expectations for both revenue and earnings. Despite a year-over-year revenue decrease, the market reacted positively to the company surpassing current forecasts. Health Catalyst also provided guidance for the second quarter and full year 2026, with the positive investor sentiment potentially due to a broader upswing in the software-as-a-service sector.
Health Catalyst, Inc. (NASDAQ:HCAT) Q1 2026 Earnings Call Transcript
Health Catalyst (NASDAQ: HCAT) reported strong Q1 2026 results, exceeding revenue and adjusted EBITDA expectations, and announced a new performance metric: total bookings. The company is undergoing a significant transformation called Project NEXUS to streamline operations, optimize costs with an anticipated $30 million in annual run rate savings, and focus on AI-driven technology solutions. Despite short-term revenue pressure from a migration strategy, the company is confident in its plan for durable, efficient growth and long-term value creation.
Health Catalyst outlines $260M-$265M 2026 revenue outlook backed by Project Nexus $30M run-rate savings
Health Catalyst (HCAT) announced a revenue outlook of $260 million to $265 million for 2026, anticipating a five-year compound annual growth rate of 10-12%. This projection is supported by Project Nexus, which is expected to generate $30 million in run-rate operating expense savings by 2026. The company also confirmed its full-year 2024 guidance and updated its 2025 outlook to $201-$205 million, reflecting a more cautious approach to near-term growth due to market challenges.
Health Catalyst Reports First Quarter 2026 Results
Health Catalyst, Inc. (Nasdaq: HCAT) reported solid first quarter 2026 results, with revenue and adjusted EBITDA exceeding expectations. The company also announced a strategic reset aimed at transforming its operating model and focusing on high-conviction technology opportunities. Health Catalyst provided forward-looking guidance, expecting total revenue of $68 million to $70 million and Adjusted EBITDA of $9 million to $10 million for the second quarter of 2026.
Health Catalyst (HCAT) Reports Strong Q1 Revenue and Strategic T
Health Catalyst Inc (HCAT) announced better-than-expected Q1 revenue of $70.76 million, exceeding analyst forecasts. The company's CEO highlighted a strategic shift toward focusing on promising technology opportunities. Despite the strong revenue, Health Catalyst's GF Score of 47/100, low financial strength and profitability rankings, and recent insider selling suggest investors should approach with caution.
Health Catalyst: Q1 Earnings Snapshot
Health Catalyst Inc. (HCAT) reported a first-quarter loss of $111 million, or $1.53 per share, though adjusted earnings were 2 cents per share. The company's revenue of $70.8 million exceeded analyst expectations. Health Catalyst anticipates second-quarter revenue between $68 million and $70 million, with a full-year outlook of $260 million to $265 million.
Health Catalyst’s (NASDAQ:HCAT) Q1 CY2026 Sales Beat Estimates, Stock Jumps 11.1%
Health Catalyst (NASDAQ:HCAT) reported Q1 CY2026 results, beating revenue expectations with $70.76 million, despite a 10.9% year-on-year decline. The stock jumped 11.1% immediately after the report, though its next quarter's revenue guidance and full-year revenue and EBITDA guidance fell below analysts' estimates. The company highlighted solid first-quarter results with revenue and adjusted EBITDA exceeding expectations, but noted challenges in long-term revenue growth and customer acquisition efficiency.
Health Catalyst Reports First Quarter 2026 Results
Health Catalyst, Inc. announced its financial results for the first quarter ended March 31, 2026, reporting total revenue of $70.756 million and adjusted EBITDA of $9.137 million, exceeding expectations. The company also provided forward-looking guidance for the second quarter and full year 2026, expecting total revenue of $68-70 million and adjusted EBITDA of $9-10 million for Q2, and $260-265 million and $30-33 million respectively for the full year. CEO Ben Albert highlighted a strategic reset aimed at transforming the operating model and focusing on high-conviction technology opportunities.
Health Catalyst's (HCAT) "Neutral" Rating Reaffirmed at Cantor Fitzgerald
Cantor Fitzgerald reaffirmed its "neutral" rating on Health Catalyst (HCAT), aligning with other brokerages that have issued cautious views and price target reductions. The stock currently holds a consensus "Hold" rating with an average target price of $2.80. Health Catalyst reported Q1 earnings of $0.08 per share, missing estimates, though revenue of $74.68 million slightly exceeded expectations.
Health Catalyst (HCAT) Set to Report Q1 Earnings with Mixed Expe
Health Catalyst (HCAT) is scheduled to release its Q1 earnings, with analysts projecting a 100% year-over-year increase in EPS despite a 12.9% revenue decline. The company, a small-cap healthcare tech provider, faces challenges with profitability and financial strength, as indicated by its GF Score™ of 49/100 and negative earnings. Insider selling activity further suggests potential concerns among company executives.
Health Catalyst (HCAT) Reports Q1: Everything You Need To Know Ahead Of Earnings
Health Catalyst (HCAT) is set to report its Q1 earnings, with market expectations pointing to a 12.9% year-on-year revenue decline. The company previously exceeded revenue expectations last quarter but provided slower guidance for the current quarter. Despite this, positive sentiment in the data analytics sector has seen HCAT's share price rise significantly over the last month.
Health Catalyst (HCAT) Reports Q1: Everything You Need To Know Ahead Of Earnings
Health Catalyst (HCAT) is set to report its Q1 earnings this Monday after market hours. Analysts predict a 12.9% year-on-year revenue decline, despite the company consistently beating Wall Street estimates in the past. Peer companies like Palantir Technologies and CLEAR Secure have already reported their Q1 results, showing revenue growth, while Health Catalyst's stock has seen a significant increase of 49.6% over the last month, with an average analyst price target of $1.79.
Health Catalyst Inc expected to post earnings of 2 cents a share - Earnings Preview
Health Catalyst Inc (HCAT) is projected to report earnings of 2 cents per share. This information comes from a Refinitiv earnings preview. The article provides financial news regarding the company's upcoming earnings report.
[Form 4] Health Catalyst, Inc. Insider Trading Activity
Health Catalyst, Inc. director Steven H. Nelson reported an acquisition of 154,808 restricted stock units (RSUs) as compensation. These RSUs were granted at no cash cost and are subject to multi-year vesting, with the first tranche vesting on May 1, 2027, and the remainder in two equal annual installments. This transaction was filed via Form 4 and indicates a neutral impact and sentiment according to Rhea-AI.
Health Catalyst (NASDAQ: HCAT) director Nelson submits initial Form 3
Health Catalyst (NASDAQ: HCAT) director Steven H. Nelson has filed an initial Form 3, which is a statement of beneficial ownership. This filing formally establishes Nelson's status as a director but does not disclose any buy, sell, or other insider trading transactions. The SEC Form 3 serves as a baseline for future disclosures of equity awards or trading activity.
Health Catalyst, Inc. (NASDAQ:HCAT) Receives Consensus Recommendation of "Hold" from Analysts
Health Catalyst, Inc. (NASDAQ:HCAT) has received a consensus "Hold" rating from analysts, with an average one-year target price of $2.7955. This recommendation comes despite recent cuts in price targets by several brokers and weak first-quarter results where the company missed EPS estimates. Hedge funds have recently adjusted their holdings, with institutional investors owning 85.00% of the company's stock.
Health Catalyst | 4: Statement of changes in beneficial ownership of securities-Officer Albert Benjamin
This document, titled "Health Catalyst | 4: Statement of changes in beneficial ownership of securities-Officer Albert Benjamin," indicates a formal filing related to changes in the beneficial ownership of securities for an officer named Albert Benjamin at Health Catalyst. Such a statement is typically a regulatory disclosure.
Health Catalyst Adds Steve Nelson to Board of Directors
Health Catalyst (HCAT) has appointed Steve Nelson, Executive Vice President and President of Aetna, to its board of directors, effective May 1, 2026. This move expands the board to seven directors and is part of a broader leadership restructuring aimed at strengthening governance. Nelson's extensive experience in the insurance sector is expected to provide valuable insights as Health Catalyst focuses on AI-enabled intelligence for health systems.
Health Catalyst to Announce First Quarter 2026 Operating Results and Host Conference Call on Monday, May 11, 2026
Health Catalyst, Inc. (Nasdaq: HCAT) will release its first quarter 2026 operating results after market close on Monday, May 11, 2026. The company will host a conference call at 5:00 pm ET on the same day to discuss the results. Interested parties can access the call via phone or a live audio webcast, with a replay available online for approximately 90 days.
Health Catalyst (HCAT) CEO receives PRSUs, sells shares to cover taxes
Health Catalyst (HCAT) CEO Albert Benjamin recently received 1,124 performance-based restricted units (PRSUs) based on the company's 2025 performance. To cover tax withholding obligations from the vesting of restricted stock units, Benjamin sold 310 common shares at $1.345 each in a mandated "sell-to-cover" transaction. Following these transactions, the CEO directly holds 1,458,792 common shares.
Health Catalyst Inc expected to post earnings of 2 cents a share - Earnings Preview
Health Catalyst Inc (HCAT) is projected to report earnings of 2 cents per share. This information is provided as an earnings preview from Refinitiv. The article is a brief news update regarding the company's upcoming financial disclosure.
Health Catalyst to post quarterly results after the close on May 11
Health Catalyst (HCAT) will release its first quarter 2026 operating results on Monday, May 11, 2026, after market close, and will host a conference call at 5:00 pm ET the same day. Following this announcement, the stock gained 5.17%, indicating a positive market reaction, with elevated trading interest and price volatility. The company's prior earnings-date announcement for Q4 2025 also saw a modest positive market reaction.
Health Catalyst (NasdaqGS:HCAT) Stock Forecast & Analyst Predictions
Health Catalyst (HCAT) is currently facing analyst concerns, with forecasts predicting a revenue decline while earnings are expected to grow significantly. The company has seen various price target reductions and negative EPS revisions due to product transitions, leadership changes, and sector challenges. Despite these headwinds, some analysts see potential for a rebound in 2026, driven by new leadership, AI investments, and the Ignite platform.
Health Catalyst adds Aetna executive to board of directors
Health Catalyst (NASDAQ: HCAT) announced the appointment of Steve Nelson, Executive Vice President and President of Aetna, to its Board of Directors. This move follows recent leadership changes and comes as the company faces a significant stock price decline, though analysts suggest it is undervalued and predict future profitability. The company continues to navigate challenges in a complex healthcare landscape as it aims to be an intelligence partner for health systems.
Health Catalyst adds Aetna executive to board of directors
Health Catalyst, Inc. (NASDAQ:HCAT) has appointed Steve Nelson, Executive Vice President and President of Aetna, to its Board of Directors, effective Friday. This appointment follows other recent leadership changes and comes as the company navigates a challenging financial landscape. Despite a significant stock price drop, analysts predict profitability for Health Catalyst this year.
Executive pay and leadership shifts at Health Catalyst (NASDAQ: HCAT)
Health Catalyst, Inc. filed an amendment to its 2025 annual report, detailing executive leadership changes including Benjamin Albert's appointment as CEO and Daniel Burton's retirement, alongside departures of the Chief Commercial and Operating Officers. The amendment also outlines executive compensation, which remains heavily performance-based, with a significant portion of 2025 target compensation at risk via bonuses and equity. Despite strong profitability as measured by Adjusted EBITDA, other growth targets underperformed, leading to only 39% vesting of annual bonus PRSUs.
Health Catalyst Adds Steve Nelson to Board of Directors
Health Catalyst (HCAT) has appointed Steve Nelson, President of Aetna, to its board of directors, effective May 1, 2026. This appointment is part of a broader leadership restructuring aimed at enhancing the company's governance and leveraging Nelson's extensive experience in the insurance and provider sectors to further its AI-driven strategy. Despite this, the stock currently holds a "Hold" rating from analysts with a $3.00 price target, and TipRanks' AI Analyst Spark rates HCAT as Neutral due to weak financial performance.
Health Catalyst Appoints Steve Nelson, President of Aetna, to Its Board of Directors
Health Catalyst has appointed Steve Nelson, Executive Vice President and President of Aetna, to its Board of Directors, effective May 1, 2026. This appointment reinforces Health Catalyst's strategic leadership enhancement, following recent CEO and Chairman changes, aiming to accelerate the company's transformation in helping health systems address cost, clinical outcomes, and consumer experience. Nelson's extensive background in healthcare, including leadership roles at Aetna, ChenMed, Duly Health and Care, and UnitedHealthcare, brings invaluable perspective to Health Catalyst as it focuses on AI-enabled technology solutions for foundational healthcare challenges.
Health Catalyst adds Aetna executive to board of directors By Investing.com
Health Catalyst (NASDAQ:HCAT) has appointed Steve Nelson, Executive Vice President and President of Aetna, to its Board of Directors, effective Friday. This appointment follows recent leadership changes at Health Catalyst, including a new CEO and Chairman of the Board. Despite the stock being down 68% over the past year, InvestingPro analysis suggests it is undervalued, with analysts predicting profitability this year.
Health Catalyst Appoints Steve Nelson to Board of Directors to Strengthen Leadership in Healthcare Intelligence
Health Catalyst, Inc. announced the appointment of Steve Nelson, Executive Vice President and President of Aetna, to its Board of Directors, effective May 1, 2026. This move is part of Health Catalyst's strategic transformation efforts, aiming to enhance the company's ability to assist healthcare systems in addressing critical challenges like cost control, clinical outcomes, and consumer experience. Nelson's extensive experience in the healthcare sector, including leadership roles at major health organizations, is expected to provide valuable insights for the company's AI-driven solutions.
